Cargando…
Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()()
BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently b...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191023/ https://www.ncbi.nlm.nih.gov/pubmed/29548882 http://dx.doi.org/10.1016/j.soard.2018.01.039 |
_version_ | 1783363654561824768 |
---|---|
author | Roberts, Geoffrey P. Kay, Richard G. Howard, James Hardwick, Richard H. Reimann, Frank Gribble, Fiona M. |
author_facet | Roberts, Geoffrey P. Kay, Richard G. Howard, James Hardwick, Richard H. Reimann, Frank Gribble, Fiona M. |
author_sort | Roberts, Geoffrey P. |
collection | PubMed |
description | BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently been implicated. OBJECTIVES: We investigated hormonal responses in lean patients after prophylactic total gastrectomy (PTG), as a model of Roux-en-Y gastric bypass without the confounding effects of obesity or massive weight loss. SETTING: University hospital, United Kingdom. METHODS: Ten participants after PTG and 9 healthy volunteers were recruited for oral glucose tolerance tests. Plasma glucose, insulin, GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glucagon, oxyntomodulin, glucagon((1-61)), and glicentin levels were assessed using immunoassays and/or mass spectrometry. RESULTS: PTG participants exhibited accelerated plasma glucose appearance, followed, in 3 of 10 cases, by hypoglycemia (<3 mM glucose). Plasma GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glicentin, and oxyntomodulin responses were elevated, and glucagon appeared to rise in PTG participants when measured with a glucagon-specific enzyme-linked immunosorbent assay. We revisited the specificity of this assay, and demonstrated significant cross-reactivity with glicentin and oxyntomodulin at concentrations observed in PTG plasma. Reassessment of glucagon with the same assay using a modified protocol, and by liquid chromatography-mass spectrometry, demonstrated suppression of glucagon secretion after oral glucose tolerance tests in both PTG and control cohorts. CONCLUSIONS: Care should be taken when assessing glucagon levels in the presence of elevated plasma levels of other proglucagon products. Substantial elevation of GLP-1 and insulin responses after PTG likely contribute to the observed hypoglycemia, and mirror similar hormone levels and complications observed in bariatric weight loss patients. |
format | Online Article Text |
id | pubmed-6191023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-61910232018-11-01 Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() Roberts, Geoffrey P. Kay, Richard G. Howard, James Hardwick, Richard H. Reimann, Frank Gribble, Fiona M. Surg Obes Relat Dis Article BACKGROUND: Altered enteroendocrine hormone responses are widely believed to underlie the beneficial effects of bariatric surgery in type 2 diabetes. While elevated postprandial glucagon-like peptide-1 (GLP-1) is considered one of the mediators, increased postprandial glucagon levels have recently been implicated. OBJECTIVES: We investigated hormonal responses in lean patients after prophylactic total gastrectomy (PTG), as a model of Roux-en-Y gastric bypass without the confounding effects of obesity or massive weight loss. SETTING: University hospital, United Kingdom. METHODS: Ten participants after PTG and 9 healthy volunteers were recruited for oral glucose tolerance tests. Plasma glucose, insulin, GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glucagon, oxyntomodulin, glucagon((1-61)), and glicentin levels were assessed using immunoassays and/or mass spectrometry. RESULTS: PTG participants exhibited accelerated plasma glucose appearance, followed, in 3 of 10 cases, by hypoglycemia (<3 mM glucose). Plasma GLP-1, peptide YY, glucose-dependent insulinotropic-polypeptide, glicentin, and oxyntomodulin responses were elevated, and glucagon appeared to rise in PTG participants when measured with a glucagon-specific enzyme-linked immunosorbent assay. We revisited the specificity of this assay, and demonstrated significant cross-reactivity with glicentin and oxyntomodulin at concentrations observed in PTG plasma. Reassessment of glucagon with the same assay using a modified protocol, and by liquid chromatography-mass spectrometry, demonstrated suppression of glucagon secretion after oral glucose tolerance tests in both PTG and control cohorts. CONCLUSIONS: Care should be taken when assessing glucagon levels in the presence of elevated plasma levels of other proglucagon products. Substantial elevation of GLP-1 and insulin responses after PTG likely contribute to the observed hypoglycemia, and mirror similar hormone levels and complications observed in bariatric weight loss patients. Elsevier 2018-05 /pmc/articles/PMC6191023/ /pubmed/29548882 http://dx.doi.org/10.1016/j.soard.2018.01.039 Text en © 2018 American Society for Metabolic and Bariatric Surgery. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Roberts, Geoffrey P. Kay, Richard G. Howard, James Hardwick, Richard H. Reimann, Frank Gribble, Fiona M. Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title | Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title_full | Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title_fullStr | Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title_full_unstemmed | Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title_short | Gastrectomy with Roux-en-Y reconstruction as a lean model of bariatric surgery()() |
title_sort | gastrectomy with roux-en-y reconstruction as a lean model of bariatric surgery()() |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6191023/ https://www.ncbi.nlm.nih.gov/pubmed/29548882 http://dx.doi.org/10.1016/j.soard.2018.01.039 |
work_keys_str_mv | AT robertsgeoffreyp gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery AT kayrichardg gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery AT howardjames gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery AT hardwickrichardh gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery AT reimannfrank gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery AT gribblefionam gastrectomywithrouxenyreconstructionasaleanmodelofbariatricsurgery |